Biologics in Sinonasal Disease
Patient Management Perspectives in Otolaryngology
Introduction:
This is a case-based learning activity designed to outline the workup and management of patients with chronic rhinosinusitis with polyps, with an emphasis on the role of biologic therapies (e.g. dupilumab and omalizumab) in patients with more severe disease and/or refractory to other management strategies.
Purpose/Abstract:
The participant who has successfully completed this program should be able to:
1. Differentiate the symptoms and physical examination findings that distinguish chronic rhinosinusitis with nasal polyps from other common nasal diseases.
2. Discuss the typical treatment algorithm for chronic rhinosinusitis with nasal polyps.
3. Discuss the treatment options for patients that fail initial surgery for chronic rhinosinusitis with nasal polyps.
4. Discuss the mechanism of action, indications, side effects and efficacy of biologic therapies used in the management of chronic rhinosinusitis with nasal polyps.
Credits
CME:1.0, MOC:1.0
Description
Course Authors:
Christopher D. Brook, MD, faculty for this accredited education activity receives consulting fees from GI Reviewers and RadMetrix.
Jordan T. Glicksman, MD, MPH, FACS, FRCSC, faculty for this accredited education activity has no relevant financial relationships with ineligible companies to disclose.
CME Planners:
Jeffrey P. Simons, MD, MMM, CME planner and AAO-HNSF Coordinator for Education has no relevant financial relationships with ineligible companies to disclose.
Robert P. Oliveri, CAE, CME planner and AAO-HNSF staff member has no relevant financial relationships with ineligible companies to disclose.
Courses in package:
